Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 86 articles:
HTML format
Text format



Single Articles


    June 2015
  1. TAGLIABUE E, Fargnoli MC, Gandini S, Maisonneuve P, et al
    MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  2. EL HAJJ P, Gilot D, Migault M, Theunis A, et al
    SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.
    Br J Cancer. 2015 Jun 11. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    May 2015
  3. FERRUCCI PF, Gandini S, Battaglia A, Alfieri S, et al
    Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Br J Cancer. 2015 May 26. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  4. SRIVASTAVA SK, Bhardwaj A, Arora S, Tyagi N, et al
    Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis.
    Br J Cancer. 2015 May 5. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  5. ALGAZI AP, Cha E, Ortiz-Urda SM, McCalmont T, et al
    The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    Br J Cancer. 2015;112:1326-31.
    PubMed     Text format     Abstract available


    March 2015
  6. RUTHERFORD MJ, Ironmonger L, Ormiston-Smith N, Abel GA, et al
    Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.
    Br J Cancer. 2015 Mar 3. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    February 2015
  7. BAGNARDI V, Rota M, Botteri E, Tramacere I, et al
    Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis.
    Br J Cancer. 2015;112:580-93.
    PubMed     Text format     Abstract available


    November 2014
  8. WARD ST, Li KK, Hepburn E, Weston CJ, et al
    The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
    Br J Cancer. 2014 Nov 18. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    October 2014
  9. LA ROSA F, Liso A, Bianconi F, Duca E, et al
    Seasonal variation in the month of birth in patients with skin cancer.
    Br J Cancer. 2014;111:1810-3.
    PubMed     Text format     Abstract available


  10. HEINZERLING L, Schuler G, Hartmann A, Schneider-Stock R, et al
    Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1679-80.
    PubMed     Text format    


  11. MENZIES AM, Wilmott JS, Long GV, Scolyer RA, et al
    Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1678-9.
    PubMed     Text format    


    September 2014
  12. FEDORENKO IV, Gibney GT, Sondak VK, Smalley KS, et al
    Beyond BRAF: where next for melanoma therapy?
    Br J Cancer. 2014 Sep 2. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    August 2014
  13. MIRZA KA, Tisdale MJ
    Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.
    Br J Cancer. 2014;111:903-8.
    PubMed     Text format     Abstract available


  14. WHIPPLE CA, Brinckerhoff CE
    BRAF melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.
    Br J Cancer. 2014 Aug 12. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  15. HOLDERFIELD M, Nagel TE, Stuart DD
    Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
    Br J Cancer. 2014;111:640-5.
    PubMed     Text format     Abstract available


    July 2014
  16. KALIRAI H, Dodson A, Faqir S, Damato BE, et al
    Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.
    Br J Cancer. 2014 Jul 24. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  17. GAMMONS MV, Lucas R, Dean R, Coupland SE, et al
    Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Br J Cancer. 2014 Jul 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    June 2014
  18. CARLINO MS, Haydu LE, Kakavand H, Menzies AM, et al
    Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Br J Cancer. 2014 Jun 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  19. JIN P, Civini S, Zhao Y, De Giorgi V, et al
    Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.
    Br J Cancer. 2014;110:2955-64.
    PubMed     Text format     Abstract available


    April 2014
  20. AZIMI A, Pernemalm M, Frostvik Stolt M, Hansson J, et al
    Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
    Br J Cancer. 2014 Apr 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  21. JIANG G, Yang CS, Xu D, Sun C, et al
    Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.
    Br J Cancer. 2014 Apr 8. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  22. WU S, Han J, Vleugels RA, Puett R, et al
    Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women.
    Br J Cancer. 2014;110:1855-61.
    PubMed     Text format     Abstract available


    March 2014
  23. CHIARION-SILENI V, Pigozzo J, Ascierto PA, Simeone E, et al
    Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
    Br J Cancer. 2014 Mar 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    February 2014
  24. SAND M, Georgas D, Hessam S, Bechara FG, et al
    Comment on 'Strong reduction of AGO2 expression in melanoma and cellular consequences'
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format    


  25. VOLLER D, Bosserhoff A
    Reply to comment on: strong reduction of AGO2 expression in melanoma and cellular consequences.
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format    


  26. POSCH C, Weihsengruber F, Bartsch K, Feichtenschlager V, et al
    Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
    Br J Cancer. 2014 Feb 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  27. LI X, Wu XB, Chen Q
    Statin use is not associated with reduced risk of skin cancer: a meta-analysis.
    Br J Cancer. 2014;110:802-7.
    PubMed     Text format     Abstract available


    January 2014
  28. DONO M, Angelini G, Cecconi M, Amaro A, et al
    Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.
    Br J Cancer. 2014 Jan 14. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    November 2013
  29. ADENIS A, Ray-Coquard I, Italiano A, Chauzit E, et al
    A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
    Br J Cancer. 2013;109:2574-8.
    PubMed     Text format     Abstract available


  30. HEINZERLING L , Baiter M, Kuhnapfel S, Schuler G, et al
    Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.
    Br J Cancer. 2013 Nov 5. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    October 2013
  31. KHOSRAVI S , Wong RP, Ardekani GS, Zhang G, et al
    Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.
    Br J Cancer. 2013 Oct 31. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  32. VOLLER D , Reinders J, Meister G, Bosserhoff AK, et al
    Strong reduction of AGO2 expression in melanoma and cellular consequences.
    Br J Cancer. 2013 Oct 29. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  33. LU J , Tang Y, Cheng Y, Zhang G, et al
    ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients.
    Br J Cancer. 2013 Oct 24. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  34. BEDOGNETTI D , Spivey TL, Zhao Y, Uccellini L, et al
    CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.
    Br J Cancer. 2013 Oct 15. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  35. OSAWA T, Ohga N, Akiyama K, Hida Y, et al
    Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.
    Br J Cancer. 2013;109:2237-47.
    PubMed     Text format     Abstract available


    August 2013
  36. PLUMMER R , Lorigan P, Brown E, Zaucha R, et al
    Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
    Br J Cancer. 2013 Aug 29. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    July 2013
  37. ZEBARY A , Jangard M, Omholt K, Ragnarsson-Olding B, et al
    KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Br J Cancer. 2013 Jul 16. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  38. MURTAS D , Maric D, De Giorgi V, Reinboth J, et al
    IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes.
    Br J Cancer. 2013;109:76-82.
    PubMed     Text format     Abstract available


    June 2013
  39. GRIEWANK KG , Murali R, Schilling B, Scholz S, et al
    TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Br J Cancer. 2013 Jun 25. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  40. SHERRILL B , Wang J, Kotapati S, Chin K, et al
    Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.
    Br J Cancer. 2013 Jun 20. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  41. KOOPMANS AE , Vaarwater J, Paridaens D, Naus NC, et al
    Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
    Br J Cancer. 2013 Jun 18. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  42. WHEELER BW , Kothencz G, Pollard AS
    Geography of non-melanoma skin cancer and ecological associations with environmental risk factors in England.
    Br J Cancer. 2013 Jun 11. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    May 2013
  43. GRANN AF , Froslev T, Olesen AB, Schmidt H, et al
    The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study.
    Br J Cancer. 2013 May 16. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  44. BOECKE A , Carstens AC, Neacsu CD, Baschuk N, et al
    TNF-receptor-1 adaptor protein FAN mediates TNF-induced B16 melanoma motility and invasion.
    Br J Cancer. 2013 May 14. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  45. MILLWARD M , Underhill C, Lobb S, McBurnie J, et al
    Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
    Br J Cancer. 2013 May 7. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    April 2013
  46. HEINZERLING L , Kuhnapfel S, Meckbach D, Baiter M, et al
    Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
    Br J Cancer. 2013 Apr 11. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    March 2013
  47. O'BOYLE G , Swidenbank I, Marshall H, Barker CE, et al
    Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
    Br J Cancer. 2013 Mar 28. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  48. EL HAJJ P , Journe F, Wiedig M, Laios I, et al
    Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.
    Br J Cancer. 2013 Mar 21. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


  49. KURIHARA M , Kirita T, Sasahira T, Ohmori H, et al
    Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma.
    Br J Cancer. 2013 Mar 19. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    February 2013
  50. WILMOTT JS , Menzies AM, Haydu LE, Capper D, et al
    BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
    Br J Cancer. 2013 Feb 12. doi: 10.1038/bjc.2013.
    PubMed     Text format     Abstract available


    October 2012
  51. ALI Z , Fisher R, Larkin J
    Targeted therapeutics in melanoma.
    Br J Cancer. 2012;107:1663.
    PubMed     Text format    


    September 2012
  52. GIRARD E , Strathdee C, Trueblood E, Queva C, et al
    Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model.
    Br J Cancer. 2012 Sep 6. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


    August 2012
  53. SEGUIN F , Carvalho MA, Bastos DC, Agostini M, et al
    The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
    Br J Cancer. 2012 Aug 14. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


    July 2012
  54. KRUIJFF S , Bastiaannet E, Francken AB, Schaapveld M, et al
    Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.
    Br J Cancer. 2012;107:570-4.
    PubMed     Text format     Abstract available


  55. WEIDE B , Elsasser M, Buttner P, Pflugfelder A, et al
    Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Br J Cancer. 2012 Jul 10. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


  56. PECUCHET N , Lebbe C, Mir O, Billemont B, et al
    Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    Br J Cancer. 2012 Jul 5. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


    April 2012
  57. FEUN LG , Marini A, Walker G, Elgart G, et al
    Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
    Br J Cancer. 2012 Apr 3. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


    March 2012
  58. WANG H , Lee S, Nigro CL, Lattanzio L, et al
    NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
    Br J Cancer. 2012 Mar 27. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


  59. HENARE K , Wang L, Wang LC, Thomsen L, et al
    Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
    Br J Cancer. 2012;106:1134-47.
    PubMed     Text format     Abstract available


  60. YAMAMOTO K , Ohga N, Hida Y, Maishi N, et al
    Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.
    Br J Cancer. 2012;106:1214-23.
    PubMed     Text format     Abstract available


    February 2012
  61. THOMAS S , Putter C, Weber S, Bornfeld N, et al
    Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study.
    Br J Cancer. 2012 Feb 21. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


    January 2012
  62. WALDMANN A , Nolte S, Weinstock MA, Breitbart EW, et al
    Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening.
    Br J Cancer. 2012 Jan 31. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


  63. SAKAIZAWA K , Goto Y, Kiniwa Y, Uchiyama A, et al
    Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
    Br J Cancer. 2012 Jan 26. doi: 10.1038/bjc.2012.
    PubMed     Text format     Abstract available


  64. XU Y , Brenn T, Brown ER, Doherty V, et al
    Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
    Br J Cancer. 2012 Jan 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    December 2011
  65. PARKIN DM , Mesher D, Sasieni P
    13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010.
    Br J Cancer. 2011;105 Suppl 2:S66-9.
    PubMed     Text format    


    November 2011
  66. ALGAZI AP , Weber JS, Andrews SC, Urbas P, et al
    Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
    Br J Cancer. 2011 Nov 29. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  67. JANJETOVIC Z , Brozyna AA, Tuckey RC, Kim TK, et al
    High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.
    Br J Cancer. 2011 Nov 17. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  68. JOURNE F , Boufker HI, Van Kempen L, Galibert MD, et al
    TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.
    Br J Cancer. 2011 Nov 1. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    October 2011
  69. KEIDAR M , Walk R, Shashurin A, Srinivasan P, et al
    Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy.
    Br J Cancer. 2011;105:1295-301.
    PubMed     Text format     Abstract available


  70. JOHNSON KJ , Carozza SE, Chow EJ, Fox EE, et al
    Birth characteristics and childhood carcinomas.
    Br J Cancer. 2011;105:1396-401.
    PubMed     Text format     Abstract available


  71. FUKUDA H , Mochizuki S, Abe H, Okano HJ, et al
    Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
    Br J Cancer. 2011 Oct 20. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    September 2011
  72. GRIGNOL V , Fairchild ET, Zimmerer JM, Lesinski GB, et al
    miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.
    Br J Cancer. 2011;105:1023-9.
    PubMed     Text format     Abstract available


  73. WEST EJ , Scott KJ, Jennings VA, Melcher AA, et al
    Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
    Br J Cancer. 2011;105:787-95.
    PubMed     Text format     Abstract available


    August 2011
  74. DE LUCA A , Lamura L, Strizzi L, Roma C, et al
    Expression and functional role of CRIPTO-1 in cutaneous melanoma.
    Br J Cancer. 2011 Aug 23. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  75. TAWBI HA , Villaruz L, Tarhini A, Moschos S, et al
    Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
    Br J Cancer. 2011 Aug 2. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    July 2011
  76. O'DAY S , Pavlick A, Loquai C, Lawson D, et al
    A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  77. EISEN T , Marais R, Affolter A, Lorigan P, et al
    Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  78. GREMEL G , Ryan D, Rafferty M, Lanigan F, et al
    Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.
    Br J Cancer. 2011 Jul 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    June 2011
  79. SIGALOTTI L , Fratta E, Parisi G, Coral S, et al
    Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format    


  80. BRAIG S , Wallner S, Junglas B, Fuchshofer R, et al
    CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


  81. DEBLACAM C , Byrne C, Hughes E, McIlroy M, et al
    HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Abstract available


    May 2011
  82. CHIARION-SILENI V , Guida M, Ridolfi L, Romanini A, et al
    Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    Br J Cancer. 2011.
    PubMed     Text format     Abstract available


    March 2011
  83. REUSCHENBACH M , Tran T, Faulstich F, Hartschuh W, et al
    High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.
    Br J Cancer. 2011.
    PubMed     Text format     Abstract available


  84. KHAN OA , Gore M, Lorigan P, Stone J, et al
    A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    Br J Cancer. 2011;104:750-5.
    PubMed     Text format     Abstract available


  85. KUROSU T , Ohga N, Hida Y, Maishi N, et al
    HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.
    Br J Cancer. 2011;104:819-29.
    PubMed     Text format     Abstract available


    February 2011
  86. WANG Y , Wang XY, Subjeck JR, Shrikant PA, et al
    Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Br J Cancer. 2011;104:643-52.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


All AMEDEO services are free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Amedeo is a Flying Publisher website.

   Design: